Abstract

Occlusive vasculitis is a rare complication of antiangiogenic therapy. Standardization of differential diagnosis of the genesis of inflammation and tactics of treatment of such patients remains an unsolved health problem. The article presents a clinical case of occlusive vasculitis and panuveitis in a patient receiving brolucezumab. Active management tactics with the use of long-term systemic steroid therapy, intravitreal administration of Ozurdex and drugs that improve microcirculation demonstrated the possibility of achieving effective treatment and preservation of objective vision Keywords: neovascular age-related macular degeneration, brolucizumab, occlusive vasculitis

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call